Eiko Lifesciences Limited has intimated the Bombay Stock Exchange (BSE) about an upcoming Board of Directors meeting scheduled for Thursday, 05th November, 2026. The primary agenda of the meeting is to consider and approve the unaudited Standalone and Consolidated Financial Results of the Company for the quarter and Half Year ended on 30th September, 2026. This disclosure is made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with the financial results preparation following Regulation 33 of the same regulations.
The board may also consider any other matters with the permission of the chair.
Pursuant to the Company's Code of Conduct and SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities has been closed for all Designated Persons (including directors, promoters, designated employees, and connected persons) since 01st October, 2026. The trading window will remain closed until 48 hours after the declaration of the unaudited Standalone and Consolidated Financial Results for the quarter ended 30th September, 2026.